# Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

> **NCT06066424** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 54 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Rimiducid
- **DRUG:** TROP2-CAR-NK Cells
- **DRUG:** Fludarabine phosphate
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06066424
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2038-04-30
- **Final completion:** 2040-04-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066424, "Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06066424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*